AWH
Aspira Women's Health Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$0.08
−15.90%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.3M | 9.2M | 9.2M | 8.2M | 6.8M |
| Cost of Revenue | 3.4M | 3.7M | 3.9M | 3.9M | 3.8M |
| Gross Profit | 6.0M | 5.5M | 5.3M | 4.3M | 3.1M |
| Operating Expenses | |||||
| R&D Expense | 2.9M | 3.3M | 4.0M | 6.0M | 5.3M |
| SG&A Expense | 13.1M | 18.5M | 20.1M | 31.1M | 30.3M |
| General & Admin Expense | 8.7M | 10.3M | 12.3M | 16.2M | 13.3M |
| Selling & Marketing Expense | 4.4M | 8.1M | 7.8M | 14.9M | 17.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 16.0M | 21.8M | 24.1M | 37.1M | 35.7M |
| Cost and Expenses | 19.4M | 25.5M | 28.0M | 39.3M | 39.4M |
| Operating Income (EBIT) | (10.1M) | (16.3M) | (18.9M) | (31.1M) | (32.6M) |
| Non-Operating | |||||
| Interest Income | — | — | 48.0K | 17.0K | — |
| Interest Expense | (13.0K) | (33.0K) | — | — | 48.0K |
| Net Interest Income | (20.0K) | (33.0K) | 48.0K | 17.0K | (48.0K) |
| Other Non-Op Income/Expense | (739.0K) | 3.2M | 2.2M | 1.3M | 933.0K |
| Non-Operating Income (excl Interest) | 1.9M | — | (2.2M) | — | — |
| EBT (Pre-Tax Income) | (10.8M) | (13.1M) | (16.7M) | (29.9M) | (31.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (10.8M) | (13.1M) | (16.7M) | (29.9M) | (31.7M) |
| Earnings from Cont. Ops | (10.8M) | (13.1M) | (16.7M) | (29.9M) | (31.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.8M) | (13.1M) | (16.7M) | (29.9M) | (31.7M) |
| Per Share | |||||
| Basic EPS | ($8.88) | ($0.93) | ($1.81) | ($3.85) | ($4.28) |
| Diluted EPS | ($8.88) | ($0.93) | ($1.81) | ($3.85) | ($4.28) |
| Revenue Per Share | $0.26 | $0.65 | $0.99 | $1.02 | $0.92 |
| Shares | |||||
| Basic Shares Outstanding | 36.4M | 14.1M | 9.2M | 8.1M | 7.4M |
| Diluted Shares Outstanding | 36.4M | 14.1M | 9.2M | 8.1M | 7.4M |
| Profitability Metrics | |||||
| EBITDA | (11.9M) | (16.2M) | (16.5M) | (30.9M) | (32.3M) |
| D&A | 77.0K | 92.0K | 199.0K | 269.0K | 339.0K |
| EBIT | (12.8M) | (16.3M) | (16.7M) | (31.1M) | (32.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025